AP NEWS

QIAGEN Launches QIAcube Connect – Next-Generation Automation for Sample Processing in Research Labs

January 7, 2019

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--Jan 7, 2019--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAcube Connect, which marks the next generation of QIAGEN’s widely used QIAcube instrument and is designed to bring the benefits of automated sample processing solution to a new level.

QIAcube Connect offers greatly enhanced ease of use and efficiency in enabling any research laboratory to automate the first steps of molecular research workflows using QIAGEN’s gold-standard spin column technologies for DNA, RNA and protein sample processing. It also offers important new digitization capabilities and full connectivity – in particular via a tablet that allows researchers to stay connected with their instrument. Automation with QIAcube Connect - which can be used with over 80 QIAGEN kits and 3,000 proven protocols - assures full standardization in purification of multiple sample types and frees researchers from repetitive and costly manual processing.

“QIAcube Connect delivers a new level of excellence in complete automation for nucleic acid extraction and purification. With its enhanced digital capabilities and connectivity, QIAcube Connect offers a new level of utility and efficiency,” said Dr. Thomas Schweins, Senior Vice President of QIAGEN’s Life Science Business Area. “The use of our gold-standard QIAGEN technologies allow researchers to experience great confidence in the valuable insights they gain from their biological samples. Many research labs, however, are challenged by the increasing complexity of sample types and protocols. QIAcube Connect is an innovative solution that addresses these challenges through best-in-class automation and will enable laboratories to become more efficient.”

Please find the full press release here

View source version on businesswire.com:https://www.businesswire.com/news/home/20190106005108/en/

CONTACT: QIAGEN

Investor Relations

John Gilardi

+49 2103 29 11711

Sarah Fakih

+49 2103 29 11457

e-mail:ir@QIAGEN.com

Public Relations

Thomas Theuringer

+49 2103 29 11826

Robert Reitze

+49 2103 29 11676

e-mail:pr@QIAGEN.com

KEYWORD: UNITED STATES EUROPE NORTH AMERICA MARYLAND GERMANY

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY RESEARCH SCIENCE

SOURCE: QIAGEN

Copyright Business Wire 2019.

PUB: 01/07/2019 02:00 AM/DISC: 01/07/2019 02:00 AM

http://www.businesswire.com/news/home/20190106005108/en

AP RADIO
Update hourly